A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma

Part of paid clinical trials in Basking Ridge, New Jersey.

Sponsor
Memorial Sloan Kettering Cancer Center
Study ID
NCT07105059
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Teclistamab — DRUG
    After the priming, patients will start Teclistamab step up dosing. Mezigdomide will not be given during the Teclistamab step up. After the priming and step-up, patients will start combination treatment with Teclistamab and Mezigdomide.
  • Mezigdomide — DRUG
    Start with 14 days of Mezigdomide. After the priming and step-up, patients will start combination treatment with Teclistamab and Mezigdomide.

Study Details

The researchers are doing this study to find out whether combining teclistamab and mezigdomide is a safe and effective treatment approach in people with relapsed/refractory multiple myeloma (MM).

Key Dates

Start date
Aug 8, 2025
Status verified
Feb 2026
Primary completion
Aug 8, 2028
Completion
Aug 8, 2028

Study Design

Enrollment
18 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Teclistamab and Mezigdomide
    The trial treatment will start with 14 days of mezigdomide priming to sensitize the myeloma cells to the bispecific antibody treatment and to stimulate and activate T-cells. After mezigdomide priming, patients will go through the step-up dosing with teclistamab- followed by combination treatment with both drugs.

Primary Outcome Measure

Number of Participants With Dose Limiting Toxicity Assessed by CTCAE v5.0 [ Time Frame: 1 year ]

Central Contacts

  • Malin Hultcrantz, MD, PhD
    646-608-3714
    [email protected]
  • Ross Firestone, MD, PhD, MS
    646-608-2014

Locations (7)

FacilityCityStateZIPSite coordinators
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)Basking RidgeNew Jersey07920
Malin Hultcrantz, MD, PhD
646-608-3714
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)MiddletownNew Jersey07748
Malin Hultzcrantz, MD, PhD
646-608-3714
Memorial Sloan Kettering Bergen (Limited Protocol Activities)MontvaleNew Jersey07645
Malin Hultcrantz, MD, PhD
646-608-3714
Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)CommackNew York11725
Malin Hultcrantz, MD, PhD
646-608-3714
Memorial Sloan Kettering Westchester (Limited Protocol Activities)HarrisonNew York10604
Malin Hultcrantz, MD, PhD
646-608-3714
Memorial Sloan Kettering Cancer Center (All Protocol Activities)New YorkNew York10065
Malin Hultcrantz, MD, PhD
646-608-3714
Memorial Sloan Kettering Nassau (Limited Protocol Activities)UniondaleNew York11553
Malin Hultcrantz, MD, PhD
646-608-3714

Find similar trials in Basking Ridge, NJ

By condition
Multiple myeloma
By specialty
OncologyBlood cancer
By research site
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)· Basking Ridge, NJMemorial Sloan Kettering Monmouth (Limited Protocol Activities)· Middletown, NJMemorial Sloan Kettering Bergen (Limited Protocol Activities)· Montvale, NJMemorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)· Commack, NYMemorial Sloan Kettering Westchester (Limited Protocol Activities)· Harrison, NYMemorial Sloan Kettering Cancer Center (All Protocol Activities)· New York, NY

Related Studies